DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Kim, Stéfano; Jary, Marine; Mansi, Laura; Benzidane, B.; Cazorla, Arnault; Demarchi, Martin; Nguyen, Thierry; Kaliski, Alexandre; Delabrousse, Éric; Bonnetain, Franck; Letondal, P; Bosset, Jean-François; Valmary‐Degano, Séverine; Borg, Christophe

doi:10.1093/annonc/mdt396

Cited by 52 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional therapeutic approaches, including triplet chemotherapy and anti‐EGFR monoclonal antibodies, have been reported as potentially effective in this setting . In our study, such treatments were used in only 4 and 2 patients, respectively, thereby largely precluding any meaningful analysis or comparison with other series.…”

Section: Discussionmentioning

confidence: 99%

“…So far, the decision-making process for advanced anal cancer patients has been based on evidence of suboptimal quality, largely consisting of anecdotal case reports; case series; phase I studies; or small, single-arm phase II studies [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. The relatively low incidence of this condition, the common pattern of clinical presentation at diagnosis, and the high success rate of definitive chemoradiotherapy for early-stage tumors have historically hampered the development of randomized clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…As with other rare cancers, randomized clinical trials are lacking, and the only available evidence to inform the management of this condition comes from a limited number of small, single-center, retrospective studies that used single-agent or combination chemotherapy regimens in heterogeneous patient populations [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. This uncertainty is reflected by the lack of strong recommendations from most international guidelines [34,35].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients

et al. 2017

View full text Add to dashboard Cite

A platinum agent plus a fluoropyrimidine and paclitaxel-based chemotherapy are active regimens for advanced AC. Clinical trials are needed to standardize treatment pathways, investigate the potential of novel therapeutics, and improve the poor prognosis of this rare condition. 2017;22:402-408 Because of the lack of randomized trials, the optimal management of advanced anal cancer is uncertain. Despite its retrospective analysis and relatively small sample size, this is the second largest study ever conducted in this setting, and, as such, it has the potential to serve as a valuable source of information for everyday clinical practice. These findings suggest that chemotherapy with a platinum agent plus a fluoropyrimidine or paclitaxel-containing regimens are reasonable treatment options for patients with inoperable locally recurrent or metastatic anal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We did not have the HPV status of our patients, so we could not validate the above-stated hypothesis. Interestingly though, a recent publication using a regimen of docetaxel, cisplatin and 5-FU plus a different taxane illustrated that 4 patients who achieved a CR had HPV-16-positive SCCA while 50% of the nonresponders were HPV-positive [21]. …”

Section: Discussionmentioning

confidence: 99%

Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer

Kim¹,

Byer

Fulp

et al. 2014

Oncology

View full text Add to dashboard Cite

Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used for treating squamous cell cancer in different organs, but its efficacy in advanced SCCA is unclear. The objective of this study is to determine the tolerability and outcome of patients with advanced SCCA on carboplatin plus paclitaxel treatment at the Moffitt Cancer Center. Methods: Retrospective analysis was conducted by looking at records from the Moffitt Cancer Center Tumor Registry from January 2007 to January 2012. Eligible patients had to have a diagnosis of SCCA and have received carboplatin plus paclitaxel every 3 weeks as part of the treatment plan. Results: Eighteen patients fulfilled the criteria; 14 were initially diagnosed with early-stage disease and received concurrent chemoradiation, but then relapsed. Median age was 56 years. Upon diagnosis of metastatic disease, 12 patients received carboplatin plus paclitaxel as a first-line treatment. Five patients had received prior systemic chemotherapy regimens and 1 had received prior local regional therapy. The response rate was high at 53% including 3 patients who achieved a complete response. Median overall survival was 12.19 months. Conclusions: Carboplatin and paclitaxel treatment shows encouraging activity in advanced SCCA.

show abstract

“…Palliative surgery does not prolong survival, but it may improve the quality of life after failure of CRT [16] . Another option is represented by amelioration induced by medical treatment with the combination of docetaxel, which allows unexpected complete and long-lasting remissions after failure of CRT and even amenability to surgery for initially non-resectable recurrences [29] . In this setting, the results of the Epitopes-HPV02 trial would contribute to our knowledge of new therapeutic options.…”

Section: Discussionmentioning

confidence: 99%

Surgery Is an Effective Option after Failure of Chemoradiation in Cancers of the Anal Canal and Anal Margin

Delhorme

Séverac²,

Waissi³

et al. 2017

Oncology

View full text Add to dashboard Cite

Background: Surgery for anal canal cancer (ACC) and anal margin cancer (AMC) is the only curative option after failure of chemoradiotherapy (CRT). This study aimed to determine the efficacy of surgery for ACC or AMC after failed CRT. Methods: This was a single-centre, retrospective study of 161 patients initially treated with CRT. We compared the survival rates of patients successfully treated by CRT with those of patients whose CRT failed (both surgically salvaged and treated palliatively). Results: Thirty-one patients underwent surgery with curative intent, 20 received palliative treatment after failure of CRT, and 110 had effective CRT. The 5-year overall survival (OS) rate was significantly higher among patients with successful CRT than among patients who underwent surgery with curative intent (86 vs. 66%, p < 0.001). On the other hand, the 5-year OS of patients treated with curative surgery was significantly better than that of patients who underwent palliative treatment (66 vs. 13.5%, p < 0.001). The postoperative morbidity and mortality rates were 32 and 3%, respectively. Considering patients with failed CRT, curative surgery was the only factor prognostic of favourable OS in the multivariate analysis. Conclusion: Curative surgery after failure of CRT for ACC or AMC remains an effective treatment to improve survival in two-thirds of cases, resulting in high but manageable morbidity.

show abstract

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma

Cited by 52 publications

References 16 publications

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients

Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer

Surgery Is an Effective Option after Failure of Chemoradiation in Cancers of the Anal Canal and Anal Margin

Contact Info

Product

Resources

About